Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Runt-related transcription factor 1–Core-binding factor subunit beta (RUNX1–CBFβ) complex, also known as the Core-binding factor (CBF) complex, is a master regulator of hematopoiesis and is essential for the development of all definitive hematopoietic lineages (UniProt P19022, Q13951). The complex consists of the DNA-binding RUNX1 subunit and the non-DNA-binding CBFβ subunit, which stabilizes RUNX1 and significantly increases its affinity for DNA (PMID: 25837516). Genetic alterations involving this complex, such as the t(8;21) and inv(16) chromosomal translocations, are among the most common mutations in acute myeloid leukemia (AML), resulting in the production of oncogenic fusion proteins that disrupt normal gene expression (PMID: 30635431). Because the interaction between RUNX1 and CBFβ is critical for the function of both wild-type and certain oncogenic forms, it has become a high-priority target for drug development. Small molecule inhibitors, such as Ro5-3335 and the AI-10-47 series, have been developed to disrupt this protein-protein interaction (PPI), effectively inhibiting the transcriptional program of leukemic cells and inducing differentiation or apoptosis (PMID: 22343824). Targeting this complex offers a potential therapeutic strategy for leukemias characterized by CBF rearrangements or RUNX1 mutations, though challenges remain regarding the impact on normal hematopoietic stem cell maintenance (PMID: 10648228).
Inhibition of the protein-protein interaction (PPI) between the RUNX1 Runt domain and the CBFβ subunit to reduce DNA binding and transcriptional activity.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Runt-related transcription factor 1–Core-binding factor subunit beta complex (RUNX1–CBFβ) (RUNX1–CBFβ).